Cidara Therapeutics, Inc. CDTX
Jan 8, 2026, 9:30 AM EST
52-week range unavailable
- YTD
- +0.22%
- 1 year
- +725.74%
- Market cap
- 5.61B
- YTD return
- +0.22%
- 1-year return
- +725.74%
- Volume
- 2.69M
- Open
- 221.38
- Previous close
- 221.38
- Day's range
- 221.38 – 221.38
Key statistics
- Enterprise value
- 5.32B
- PEG ratio
- -1.58
- Price / sales
- 0.00
- Price / book
- 8.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -23.59%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2025 | Sep 30, 2025 | -1.34 | -3.10 | -1.76 | -131.34% |
| Aug 7, 2025 | Jun 30, 2025 | -1.87 | -1.65 | +0.22 | +11.76% |
| May 8, 2025 | Mar 31, 2025 | -5.45 | -1.66 | +3.79 | +69.54% |
| Mar 6, 2025 | Dec 31, 2024 | -5.28 | -5.38 | -0.10 | -1.89% |
| Nov 7, 2024 | Sep 30, 2024 | -5.22 | -2.38 | +2.84 | +54.41% |
| Aug 13, 2024 | Jun 30, 2024 | -3.94 | -19.99 | -16.05 | -407.36% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2025 | Guggenheim | down | Buy | Neutral |
| Nov 14, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 14, 2025 | Needham | down | Buy | Hold |
| Nov 7, 2025 | RBC Capital | main | Outperform | Outperform |
| Nov 7, 2025 | Needham | main | Buy | Buy |
| Oct 21, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 38
- Website
- msd.platform-apps.io
News
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You Sell? 
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight 
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight 
3,187 Shares in Cidara Therapeutics, Inc. $CDTX Bought by ANB Bank 
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Hold” from Analysts 
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? 
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Hold” from Brokerages 
3 Potential Mid-Cap Biotech Buyout Targets In 2026 
Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX 
Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
Your note
Sign in to keep a note on CDTX — it syncs with the Stock Master app.